GNPXCongressional Stock Trades
Genprex, Inc. Common Stock
Pharmaceutical Preparations
Congressional stock trades in Genprex, Inc. Common Stock (GNPX) from House and Senate STOCK Act filings. See which members of Congress bought or sold, disclosed amounts, and filing dates.
Total Trades
4
Politicians Trading
1
Last Traded
Feb 5, 2026
Trading History
| Politician | Notified | Traded | Type | Amount | Change |
|---|---|---|---|---|---|
| Tim MooreR | Feb 20, 2026 | Feb 5, 2026 | Buy | $1,001 - $15,000 | +76.02% |
| Tim MooreR | Jan 7, 2026 | Dec 18, 2025 | Buy | $1,001 - $15,000 | +58.99% |
| Tim MooreR | Dec 2, 2025 | Nov 7, 2025 | Buy | $1,001 - $15,000 | -18.05% |
| Tim MooreR | Nov 12, 2025 | Oct 29, 2025 | Buy | $15,001 - $50,000 | -48.04% |
Price History
About Genprex, Inc. Common Stock
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.